Boehringer Ingelheim and Priaxon Collaborates to Research and Develop Novel Treatments for Cancer
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Boehringer Ingelheim and Priaxon entered into a worldwide collaboration to research and develop mdm2/p53 inhibitors for the treatment of cancer. Priaxon is providing its proprietary small molecule drug discovery expertise which is particularly suited to investigate inhibition of protein-protein interactions.
p53 is a human tumor suppressor protein. It has been shown that in tumors with wild-type p53, the restoration of p53 tumor-suppressive functions can be achieved by blocking a cellular interaction of mdm21 and p53. This may reactivate the “genome guardian” function of p53 and is therefore an interesting approach for treating various oncological indications.
“Our collaboration with Boehringer Ingelheim and its experts in oncology provides the resources and the capabilities to drive this programme forward. Both Boehringer Ingelheim and Priaxon are looking forward to working together with the goal to develop a small molecule inhibitor for this protein-protein interaction of high potential.”
Under the terms of the collaboration and license agreement, Boehringer Ingelheim will lead development and commercialization of the potential mdm2/p53 inhibitor products to capitalize on its global marketing and sales expertise.
Boehringer Ingelheim will pay significant up-front and near-term payments to Priaxon including research funding to support further discovery efforts. In addition, Priaxon will be eligible to receive from Boehringer Ingelheim EUR 86 million in milestone payments upon achievement of certain development, regulatory and commercial milestones as well as royalties on potential future net sales of products.
The companies will work jointly to identify and advance candidates into pre-clinical development. Thereafter, Boehringer Ingelheim will drive the development and commercialization of the potential cancer treatments arising from the collaboration.
"We are delighted to work with Priaxon on novel targeted cancer therapies, to further broaden our Oncology Pipeline. The discovery of p53 and its protein-protein interactions in a broad range of human cancers has been a milestone in cancer biology, yet finding potent inhibitors of these interactions has been challenging. With our partners, we see a significant potential for this treatment modality in patients with locally advanced or metastatic cancers for whom available treatment options are not satisfactory," said Dr Wolfgang Rettig, Corporate Senior Vice President Research at Boehringer Ingelheim.
p53 is a human tumor suppressor protein. It has been shown that in tumors with wild-type p53, the restoration of p53 tumor-suppressive functions can be achieved by blocking a cellular interaction of mdm21 and p53. This may reactivate the “genome guardian” function of p53 and is therefore an interesting approach for treating various oncological indications.
“Our collaboration with Boehringer Ingelheim and its experts in oncology provides the resources and the capabilities to drive this programme forward. Both Boehringer Ingelheim and Priaxon are looking forward to working together with the goal to develop a small molecule inhibitor for this protein-protein interaction of high potential.”
Under the terms of the collaboration and license agreement, Boehringer Ingelheim will lead development and commercialization of the potential mdm2/p53 inhibitor products to capitalize on its global marketing and sales expertise.
Boehringer Ingelheim will pay significant up-front and near-term payments to Priaxon including research funding to support further discovery efforts. In addition, Priaxon will be eligible to receive from Boehringer Ingelheim EUR 86 million in milestone payments upon achievement of certain development, regulatory and commercial milestones as well as royalties on potential future net sales of products.
The companies will work jointly to identify and advance candidates into pre-clinical development. Thereafter, Boehringer Ingelheim will drive the development and commercialization of the potential cancer treatments arising from the collaboration.
"We are delighted to work with Priaxon on novel targeted cancer therapies, to further broaden our Oncology Pipeline. The discovery of p53 and its protein-protein interactions in a broad range of human cancers has been a milestone in cancer biology, yet finding potent inhibitors of these interactions has been challenging. With our partners, we see a significant potential for this treatment modality in patients with locally advanced or metastatic cancers for whom available treatment options are not satisfactory," said Dr Wolfgang Rettig, Corporate Senior Vice President Research at Boehringer Ingelheim.
